Related Experiment Video
Updated: Aug 14, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Vagus nerve stimulation does not lead to significant changes in body weight in patients with epilepsy
Mikhail S Koren1, Mark D Holmes
1Division of Endocrinology, Department of Medicine, University of Washington, Seattle, WA, USA.
Background:
Vagus nerve stimulation (VNS) is an FDA-approved treatment for medically intractable epilepsy. The effect of this therapy on body weight is unclear. VNS could cause weight loss by engaging vagal afferents from the gastrointestinal tract mediating satiety.
Methods:
We performed a retrospective analysis of body weight changes over a period up to 2 years following VNS implantation. We studied 21 patients (13 M/8 F) 35 +/- 12 years old, who received a Cyberonics VNS Therapy System for medically intractable epilepsy between April 1998 and May 2004. The mean +/- SD duration of follow-up was 613.1 +/- 389.1 days. The study had 80% power with a type I error of 0.05 to detect a 5% weight change. Data were analyzed with repeated-measures ANOVA.
Results:
Weight changes relative to baseline at 30, 60, 120, 360, 480, and 720 days were -0.17 +/- 2.33, +0.33 +/- 2.64, -0.32 +/- 3.56, +1.09 +/- 5.97, +1.06 +/- 7.47, and +0.33 +/- 3.69%, respectively. At all time points these differences failed to reach statistical significance.
Conclusions:
Vagus nerve stimulation with parameters typically used in the treatment of patients with epilepsy was not associated with clinically significant weight changes. A well-controlled prospective study is necessary for more precise evaluation of the effect of VNS therapy on body weight.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

